Michelle B. Riba, MD, of the University of Michigan Rogel Cancer Center, discusses the prevalence of distress in patients with cancer, the need for a quick and simple screening method to identify patients with distress, and strategies for improving integration of psychosocial care into routine cancer care.
James L. Mohler, MD, of the Roswell Park Comprehensive Cancer Center, discusses updated recommendations in prostate cancer: more specificity for family history and genomic sequencing, as well as the evolving uses of androgen-deprivation therapy.
Frederick L. Locke, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses recent approvals of chimeric antigen receptor T-cell therapies in leukemia and lymphoma, and how clinicians are using infrastructure, navigation, and early referrals to maximize response and minimize toxicity.
Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new adjuvant therapy options for patients with pancreatic cancer, and germline testing, including testing for microsatellite instability/mismatch repair genes as well as molecular analysis of all tumors.
Chrysalyne Schmults, MD, of Brigham and Women’s Hospital, discusses treatment strategies in these nonmelanoma skin cancers, including surgery, forthcoming staging systems, and ongoing trials combining adjuvant radiotherapy and immunotherapy.
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses major findings over the past 12 months in kidney cancer, including combination immunotherapies and trends in surgical oncology.
